Transcription Factor SAP30 Is Involved in the Activation of NETO2 Gene Expression in Clear Cell Renal Cell Carcinoma


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Clear cell renal cell carcinoma (ccRCC) is a common oncourological disease with a high mortality level. The incidence of this type of cancer is constantly increasing, while molecular mechanisms involved in the disease initiation and progression remain far from being fully understood. A problem of the search for novel markers is crucial for improvement of diagnosis and therapy of ccRCC. We have previously found that the disease is characterized by increased expression of the NETO2 gene. In the present study, we showed that isoform 1 (NM_018092.4) makes the main contribution to the upregulation of this gene. Using original CrossHub software, “The Cancer Genome Atlas” (TCGA) project data were analyzed to identify possible mechanisms of NETO2 gene activation in ccRCC. The absence of significant contribution of methylation to the increase of mRNA level of the gene was observed. At the same time, a number of genes encoding transcription factors, which could potentially regulate the expression of NETO2 in ccRCC, were identified. Three such genes (MYCBP, JMY, and SAP30) were selected for the further analysis of their mRNA levels in a set of ccRCC samples with quantitative PCR. We showed a significant increase in mRNA level of one of the examined genes, SAP30, and revealed its positive correlation with NETO2 gene expression. Thus, upregulation of NETO2 gene is first stipulated by the isoform 1 (NM_018092.4), and the probable mechanism of its activation is associated with the increased expression of SAP30 transcription factor.

Sobre autores

A. Snezhkina

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

K. Nyushko

National Medical Research Radiological Center

Email: rhizamoeba@mail.ru
Rússia, Moscow, 125284

A. Zaretsky

Pirogov Russian National Research Medical University; Evrogen Lab LLC

Email: rhizamoeba@mail.ru
Rússia, Moscow, 117997; Moscow, 117437

D. Shagin

Pirogov Russian National Research Medical University

Email: rhizamoeba@mail.ru
Rússia, Moscow, 117997

A. Sadritdinova

Engelhardt Institute of Molecular Biology; National Medical Research Radiological Center

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991; Moscow, 125284

M. Fedorova

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

Z. Guvatova

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

I. Abramov

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

E. Pudova

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

B. Alekseev

National Medical Research Radiological Center

Email: rhizamoeba@mail.ru
Rússia, Moscow, 125284

A. Dmitriev

Engelhardt Institute of Molecular Biology

Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991

A. Kudryavtseva

Engelhardt Institute of Molecular Biology; National Medical Research Radiological Center

Autor responsável pela correspondência
Email: rhizamoeba@mail.ru
Rússia, Moscow, 119991; Moscow, 125284

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Pleiades Publishing, Inc., 2018